Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for Coeptis Therapeutics Holdings (COEP) over the last 5 years, with Q3 2025 value amounting to -$89967.0.

  • Coeptis Therapeutics Holdings' Change in Accured Expenses fell 21201.71% to -$89967.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$403510.0, marking a year-over-year decrease of 28613.37%. This contributed to the annual value of $235000.0 for FY2024, which is 3764.56% down from last year.
  • Coeptis Therapeutics Holdings' Change in Accured Expenses amounted to -$89967.0 in Q3 2025, which was down 21201.71% from -$186238.0 recorded in Q2 2025.
  • In the past 5 years, Coeptis Therapeutics Holdings' Change in Accured Expenses registered a high of $163093.0 during Q1 2024, and its lowest value of -$465491.0 during Q4 2021.
  • Its 5-year average for Change in Accured Expenses is -$12626.9, with a median of $12031.0 in 2021.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 146680.64% in 2022, then crashed by 29895.31% in 2025.
  • Coeptis Therapeutics Holdings' Change in Accured Expenses (Quarter) stood at -$465491.0 in 2021, then skyrocketed by 61.72% to -$178178.0 in 2022, then skyrocketed by 93.78% to -$11083.0 in 2023, then soared by 164.35% to $7132.0 in 2024, then crashed by 1361.46% to -$89967.0 in 2025.
  • Its Change in Accured Expenses was -$89967.0 in Q3 2025, compared to -$186238.0 in Q2 2025 and -$134437.0 in Q1 2025.